MO trades above its 50‑day and 200‑day moving averages, with the 20‑day EMA recently crossing the 50‑day EMA, indicating upward momentum. Its balance sheet holds roughly $13 B in cash and a 9.45% dividend yield, reinforcing valuation strength.

Investor enthusiasm is high after Altria announced its 61st consecutive dividend increase, cementing its status as a premium income stock. Analyst upgrades and strong social‑media buzz keep market sentiment firmly bullish.

While FDA regulatory risk remains, a 57‑year dividend growth streak and solid cash flow mitigate long‑term concerns. Over a 5‑year horizon the defensive positioning and high yield support a bullish outlook.

The 14‑day RSI is at 58 and MACD turned positive, with volume 12% above its 30‑day average, signaling a technical buy. Price has held above the $68 support level, confirming the upward trend.